Cellusion moves the HQs in Nihonbashi-Kobuna Area


TOKYO (August 1, 2022)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced headquarters moves Nihonbashi-Kobuna area from Nihonbashi-Muromachi area. Nihonbashi has been known as town of medicine from 17 centuries. There are many pharmaceuticals, biotech startups, and healthcare related companies located in this district. As a result, Nihonbashi now plays the center of Japanese healthcare ecosystem. Cellusion keep locating its HQs in Nihonbashi area to utilize the tight connection with the communities. By enhancing the new office capacity, Cellusion will not only accelerate our regenerative medicine product development, but also explore our business opportunities more at the same time.

[About new headquarters]
Address: #801 H1O Nihonbashi-Kobuna bld., 8-6 Nihonbashi-Kobuna, Chuo, Tokyo, 103-0024, JAPAN
TEL: +81-3-5843-1785 (not changed)
First day of the operation: August 8th, 2022

[About Cellusion Inc.]
Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi Cells. Cellusion’s mission is to a community the clear vision of the future with cellular technology breakthrough

Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarters :8-6 Nihonbashi-Kobuna, Chuo, Tokyo, 103-0024, JAPAN
Founded : January 2015

Back to the List